Dr. Edward M. Bednarczyk |
|
University at Buffalo Pharmacy and Pharmaceutical Sciences Pharmacy Practice ChairAppointed: 2007 University at Buffalo Clinical Research Center Interim DirectorAppointed: 2004 University at Buffalo School of Pharmacy and Pharmaceutical Sciences Pharmacy Practice Clinical Associate ProfessorAppointed: 2002 University at Buffalo School of Medicine and Biomedical Sciences Nuclear Medicine Research Assistant ProfessorAppointed: 1993 |  |
Mailing Address3435 Main St. University at Buffalo Department of Nuclear Medicine 105 Parker Hall Buffalo, New York 14214-3007United States | Contact Information |
Qualifications
Fellowship, University Hospitals of Cleveland, Cardiovascular Pharmacology, 1989.
Pharm.D., Medical University of South Carolina, Pharmacy, 1987.
Resident, Buffalo General Hospital, Hospital Pharmacy, 1985.
B.Sc., University at Buffalo, Pharmacy, 1984.
Expertise and Research Interests
My research interests can be broadly catergorized as the application of molecular imaging techniques such as positron emission tomography (PET) to the drug assessment process. My recent work has focused in on the measurement of cerebral blood flow in migraine headache, a disorder that effects 10% of the US population. My work centers on the measurement of cerebral blood flow (CBF) in migraine headache, as well as measurement of the response of CBF to migraine therapy as well as experimental models of migraine.
The characteristics of positron emitting radionuclides often make them ideal tracers for measuring drug effects. This includes the labelling of drugs with commonly used PET radionuclides such as C-11, or F-18. The ubiquitous nature of these nuclides allows for creation of labelled drugs nearly identical to their unlabelled counterparts. Through this technique I have been able to follow a commonly used inhaled steroid as it deposits in the airways, and explain the duration of action seen with this drug. A second area is the assessment of drug toxicity, using PET to measure drug effects on brain glucose utilization. PET has been used very effectively to measure brain glucose uptake as a means of supporting the diagnosis of numerous disorders including Parkinson's disease, Alzheimer's disease, and seizure disorders. These diseases produce characteristic reductions in brain metabolism. We are using this same technique to investigate drug effects on brain metabolism, particularly those drugs with either particularly severe toxicities (such as seizures) or which are used in patients who might be particularly susceptible to these toxicities.
The characteristics of positron emitting radionuclides often make them ideal tracers for measuring drug effects. This includes the labelling of drugs with commonly used PET radionuclides such as C-11, or F-18. The ubiquitous nature of these nuclides allows for creation of labelled drugs nearly identical to their unlabelled counterparts. Through this technique I have been able to follow a commonly used inhaled steroid as it deposits in the airways, and explain the duration of action seen with this drug. A second area is the assessment of drug toxicity, using PET to measure drug effects on brain glucose utilization. PET has been used very effectively to measure brain glucose uptake as a means of supporting the diagnosis of numerous disorders including Parkinson's disease, Alzheimer's disease, and seizure disorders. These diseases produce characteristic reductions in brain metabolism. We are using this same technique to investigate drug effects on brain metabolism, particularly those drugs with either particularly severe toxicities (such as seizures) or which are used in patients who might be particularly susceptible to these toxicities.
Other Expertise
Reviewer for the following journals:
Pharmacotherapy
The Annals of Pharmacotherapy
Archives of Family Medicine
Committee member:
Radioactive Drug Research Committee
Pharmacotherapy
The Annals of Pharmacotherapy
Archives of Family Medicine
Committee member:
Radioactive Drug Research Committee
Keywords
COS Keywords:
Alzheimer's Disease, Blood Flow, Cardiology, Cardiovascular System, Headaches, Medical or Diagnostic Imaging, Neuroimaging, Nuclear Medicine, Pain, Parkinson's Disease, Pharmacology, Pharmacy, Radiology.Additional Terms:
Cardiovascular, Headache, Migraine, Pharmacology, Positron Emission Tomography.Languages
(Reading, Writing, Speaking)
Polish: (Functional, Basic, Fluent)
Memberships
Academy for Molecular Imaging/SNIDD
American College of Clinical Pharmacy
American Headache Society
American Pharmacists Association
American Society for Clinical Pharmacology and Therapeutics
American Society of Health-System Pharmacists
International Headache Society
Society of Nuclear Medicine
Honors and Awards
2002, Fellow,
American College of Clinical Pharmacy
Previous Positions
1993-2000, Director,
Clinical Pharmacokinetics Lab, MFHCS,
PET Program
1993-2002, Clinical Assistant Professor,
University at Buffalo,
School of Pharmacy and Pharmaceutical Sciences,
Pharmacy Practice
1991-1993, Assistant Professor,
Case Western Reserve University,
School of Medicine,
Medicine, Radiology,
Cardiology
1991-1993, Adjunct Clinical Instructor,
University at Buffalo,
School of Pharmacy and Pharmaceutical Sciences,
Pharmacy Practice
1989-1991, Senior Instructor,
Case Western Reserve University,
School of Medicine,
Medicine, Radiology,
Cardiology
Funding Received
- Pfizer Pharmaceuticals: Assessment of opiate receptor occupancy using 11C-carfentanil, $376,000, Jan to Dec 31, 2004.
- United States Department of Defense (DOD): A comparison of cerebral blood flow in migraineurs during, $114,000, 8/95 to 8/97.
- Pfizer: Central Dopamine-2 receptor occupancy in schizophrenia patients following multiple oral doses of CP-903,397 using C-11 raclopride, 274,088, 2006 to 2007.
- Pfizer: Assessment of mu-opiate receptor occupancy in healthy adult volunteers after single dose of CP-866,087 using 11C-carfentanil, 120,898, 2005 to 2006.
- Robert-Wood Johnson Pharmaceutical Research Institute: Effect of topiramate on nitroglycerin induced headache in migraineurs; assessment by H215O PET, $123,497, 1999 to 2001.
- Rhone-Poulenc Rorer Pharmaceuticals: Regional distribution of C-11 labeled triamcinolone aceto, $22,650, 1/93 to 12/93.
- Sandoz Pharmaceuticals: Management of nifedipine induced gingival hyperplasia, $20,912, 1/93 to 12/93.
Publications
- Constantinescu R, McDermott MP, Dicenzo R, de Blieck EA, Hyson HC, Beal MF, Bednarczyk EM, Bogdanov M, Metakis LJ, Browne SE, Lorenzo BJ, Ravina B, Kieburtz K (Dec 2007) A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone)., Journal of Clinical Pharmacology, 47 (12), 1580-6
- Kassab MY, Majid A, Bakhtar O, Farooq MU, Patel K, Bednarczyk EM (Oct 2007) Transcranial Doppler measurements in migraine and nitroglycerin headache., The Journal of Peadache and Pain, 8 (5), 289-93
- Tomilo DL, Smith PF, Ogundele AB, Difrancesco R, Berenson CS, Eberhardt E, Bednarczyk E, Morse GD (Mar 2006) Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers., Pharmacotherapy, 26 (3), 341-6
- Giglio P, Bednarczyk EM, Weiss K, Bakshi R (Dec 2005) Syncope and head CT scans in the emergency department., Emergency radiology, 12 (1-2), 44-6
- Zubeldia JM, Bednarczyk EM, Baker JG, Nabi HA (Aug 2005) The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases, Cancer Biotherapy & Radiopharmaceuticals, 20 (4), 450-6
- Guarasci DT, Trinh le HN, Baeumler GR, Bednarczyk EM, Compounded versus proprietary sincalide for evaluation of gallbladder ejection fraction, The Annals of Pharmacotherapy, 38(3), 428-32, Mar 2004
- Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, Johnson S, Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis, Dementia and Geriatric Cognitive Disorders, 17 Suppl 1, 40-8, 2004
- Bednarczyk, EM, Mayer D, Wong LK (2004) Nuclear Pharmacy Education in ACPE-Accredited Colleges of Pharmacy, Journal of Pharmacey Education, 68 (1), article 6
- Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, Johnson S (2004) Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis, Dementia and Geriatric Cognitive Disorders, 17 Suppl 1, 40-8
- Mayer D, Bednarczyk EM, Interaction of colony-stimulating factors and fluorodeoxyglucose f(18) positron emission tomography, The Annals of Pharmacotherapy, 36(11), 1796-9, Nov 2002
- Bednarczyk EM, Wack DS, Kassab MY, Burch K, Trinidad K, Haka M, Gona J (Nov 2002) Brain blood flow in the nitroglycerin (GTN) model of migraine: measurement using positron emission tomography and transcranial Doppler, Cephalalgia : an International Journal of Headache, 22 (9), 749-57
- Bednarczyk EM, Remler B, Weikart C, Nelson AD, Reed RC, Global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache, Neurology, 50(6), 1736-40, June 1998
- Westbrook P, Bednarczyk EM, Carlson M, Sheehan H, Bissada NF (July 1997) Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine, Journal of Periodontology, 68 (7), 645-50
- Bednarczyk EM, Furniss SM, Green JA, Munger MA. (1997) Evaluation of the indomethacin nitroglycerin interaction using positron emission tomography, Journal of Cardiovascular Pharmacology, 30, 732-2
- Panacek EA, Bednarczyk EM, Dunbar LM, Foulke, GE, Holcslaw, TL, Comparative study of the dopamine-1 agonist fenoldopam and sodium nitroprusside in the treatment of severe hypertension, Acad Emerg Med, 2, 959-65, 1995
- Bednarczyk EM, Miraldi F, Nelson D, Little D, Leisure G, Adler L, Berridge M, Green J, Assessment of the effect of ciprofloxacin vs nalidixic acid on cerebral blood flow, and metabolism, in healthy subjects via positron emission tomography, Pharmacotherapy, 14, 153-61, 1994
- Gardner SF, Lazarus HM, Bednarczyk EM, Creger RJ, Miraldi FD, Leisure G, Green JA, High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography, Bone Marrow Transplantation, 12(2), 139-44, August 1993
- Bednarczyk EM, Green JA, Nelson AD, Leisure GP, Little D, Adler LP, Berridge MS, Panacek EA, Miraldi FD, Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by positron emission tomography, Pharmacotherapy, 12(5), 369-75, 1992
- Bednarczyk EM, Green JA, Nelson AD, Leisure GA, Little D, Adler LP, Berridge MS, Panacek EA, Miraldi FD, Comparison of the effect of temafloxacin, ciprofloxacin, or placebo on cerebral blood flow, glucose, and oxygen metabolism in healthy subjects by means of positron emission tomography, Clinical Pharmacology and Therapeutics, 50(2), 165-71, August 1991
- Gardner SF, Green JA, Bednarczyk EM, Nelson AD, Leisure G, Miraldi F (February 1991) An assessment of cerebral blood flow and metabolism after fleroxacin therapy, Journal of Clinical Pharmacology, 31 (2), 151-7
- Bednarczyk EM, Rutherford WF, Leisure G, Munger MA, Panacek EA, Miraldi F, Green JA, Hyperventilation-induced reduction in cerebral blood flow: Assessment by positron emission tomography, DICP Ann Pharmacother, 24, 456-60, 1990
- Kassab MY, Majid A, Farooq MU, Azhary H, Hershey LA, Bednarczyk EM, Graybeal DF, Johnson MD, Transcranial Doppler: an introduction for primary care physicians., JABFM, 20 (1), 65-71
- Kassab MY, Majid A, Farooq MU, Azhary H, Hershey LA, Bednarczyk EM, Graybeal DF, Johnson MD, Transcranial Doppler: an introduction for primary care physicians., Journal of the American Board of Family Medicine : JABFM, 20 (1), 65-71
Profile Details
Last Updated: 2/22/2008
COS Expertise ID #391068
Reference this profile directly: http://myprofile.cos.com/bednarce68
Individual Expertise profile of Edward M. Bednarczyk, Copyright Edward M. Bednarczyk.
© COS ExpertiseTM, 2008, ProQuest LLC All rights reserved.